EML4 and non-small cell lung carcinoma: Our work also confirms the low incidence (7/208, 3.37%) of the EML4-ALK translocation among unselected NSCLC patients, which is consistent with the meta-analysis of clinical characteristics associated with the EML4-ALK translocation in the published literature (4.84%).